[go: up one dir, main page]

PT774962E - Utilizacao de dha como uma composicao farmaceutica - Google Patents

Utilizacao de dha como uma composicao farmaceutica

Info

Publication number
PT774962E
PT774962E PT96919911T PT96919911T PT774962E PT 774962 E PT774962 E PT 774962E PT 96919911 T PT96919911 T PT 96919911T PT 96919911 T PT96919911 T PT 96919911T PT 774962 E PT774962 E PT 774962E
Authority
PT
Portugal
Prior art keywords
pct
dha
pharmaceutical composition
sec
fatty acids
Prior art date
Application number
PT96919911T
Other languages
English (en)
Inventor
Barbara Jacqueline Stordy
Original Assignee
Nutricia Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutricia Nv filed Critical Nutricia Nv
Publication of PT774962E publication Critical patent/PT774962E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Fats And Perfumes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Cephalosporin Compounds (AREA)
PT96919911T 1995-05-25 1996-05-24 Utilizacao de dha como uma composicao farmaceutica PT774962E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9510636.5A GB9510636D0 (en) 1995-05-25 1995-05-25 Fatty acid treatment

Publications (1)

Publication Number Publication Date
PT774962E true PT774962E (pt) 2004-09-30

Family

ID=10775045

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96919911T PT774962E (pt) 1995-05-25 1996-05-24 Utilizacao de dha como uma composicao farmaceutica

Country Status (17)

Country Link
US (1) US6150411A (pt)
EP (1) EP0774962B1 (pt)
JP (1) JPH10503531A (pt)
KR (1) KR970704433A (pt)
AT (1) ATE264676T1 (pt)
AU (1) AU722474B2 (pt)
CA (1) CA2195979A1 (pt)
DE (1) DE69632236T2 (pt)
DK (1) DK0774962T3 (pt)
ES (1) ES2217317T3 (pt)
FI (1) FI970298A (pt)
GB (1) GB9510636D0 (pt)
HK (1) HK1012575A1 (pt)
NO (1) NO970317L (pt)
PT (1) PT774962E (pt)
WO (1) WO1996037200A1 (pt)
ZA (1) ZA964215B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2653503A1 (en) * 1998-10-15 2000-04-20 Dsm Ip Assets B.V. The use of ara as a supplement for a lactating woman
KR100341109B1 (ko) * 1999-03-10 2002-06-20 이인수 인식력 및 기억력 증강용 식이 조성물
US7112609B2 (en) * 1999-06-01 2006-09-26 Drugtech Corporation Nutritional supplements
US6258846B1 (en) * 1999-06-01 2001-07-10 Drugtech Corporation Nutritional supplements
GB9918023D0 (en) 1999-07-30 1999-09-29 Unilever Plc Skin care composition
US6479545B1 (en) * 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
GB9923738D0 (en) * 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
ATE363486T1 (de) 2001-07-27 2007-06-15 Neptune Technologies & Bioress Flavonoide und mehrfach ungesättigte fettsäuren enthaltende natürliche phospholipide maritimen ursprungs sowie deren anwendungen
US20050130937A1 (en) 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
US8052992B2 (en) 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
US7935365B2 (en) 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
TWI365716B (en) * 2003-12-02 2012-06-11 Suntory Holdings Ltd Oil or fat and oil compositions containing phospholipids and a long-chain polyunsaturated fatty acid supply compound, and food using same
EP1713463A4 (en) * 2004-01-19 2009-03-18 Martek Biosciences Corp REELIN DYSFUNCTION OR DICTION AND ASSOCIATED TECHNIQUES
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US7998500B2 (en) 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US20070166411A1 (en) * 2005-12-16 2007-07-19 Bristol-Myers Squibb Company Nutritional supplement containing long-chain polyunsaturated fatty acids
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
GB0813599D0 (en) * 2008-07-24 2008-09-03 Pharma Marine As Method
NO2493478T3 (pt) 2009-10-29 2018-07-21
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US9233114B2 (en) 2013-12-05 2016-01-12 Buriva, LLC Dietary supplement containing phospholipid-DHA derived from eggs
US9216199B2 (en) 2013-12-05 2015-12-22 Buriva, LLC Nutritional supplement containing phospholipid-DHA derived from eggs
US9549937B2 (en) 2013-12-05 2017-01-24 Burvia, LLC. Composition containing phospholipid-DHA and folate
US9610302B2 (en) 2013-12-05 2017-04-04 Buriva, LLC. Composition containing phospholipid-DHA and B vitamins
WO2017207124A1 (en) * 2016-06-01 2017-12-07 Nestec S.A. Composition for use in the prophylaxis of allergic disease
WO2023102170A1 (en) * 2021-12-02 2023-06-08 The Regents Of The University Of California Compositions and methods for inhibiting seizures

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
EP0711503A3 (en) * 1994-11-14 1997-11-26 Scotia Holdings Plc Milk fortified with GLA and/or DGLA

Also Published As

Publication number Publication date
EP0774962A1 (en) 1997-05-28
NO970317D0 (no) 1997-01-24
EP0774962B1 (en) 2004-04-21
NO970317L (no) 1997-01-24
CA2195979A1 (en) 1996-11-28
US6150411A (en) 2000-11-21
GB9510636D0 (en) 1995-07-19
KR970704433A (ko) 1997-09-06
FI970298A0 (fi) 1997-01-24
FI970298A (fi) 1997-01-24
AU722474B2 (en) 2000-08-03
ATE264676T1 (de) 2004-05-15
DE69632236T2 (de) 2005-04-14
JPH10503531A (ja) 1998-03-31
DK0774962T3 (da) 2004-08-09
ZA964215B (en) 1996-12-04
DE69632236D1 (de) 2004-05-27
AU5827796A (en) 1996-12-11
HK1012575A1 (en) 1999-08-06
ES2217317T3 (es) 2004-11-01
WO1996037200A1 (en) 1996-11-28

Similar Documents

Publication Publication Date Title
PT774962E (pt) Utilizacao de dha como uma composicao farmaceutica
TW429145B (en) Pharmaceutical composition for treating schizophrenia, tardive dyskinesia, depression, and alzheimer's disease comprising EPA/SA
ATE216230T1 (de) Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen
ES2053990T3 (es) Composiciones de acidos grasos esenciales.
GB9220667D0 (en) Improvements in or relating to dioic acids
MY117596A (en) Fatty acid esters as bioactive compounds
DE69409969D1 (de) Salze der mehrfach ungesättigten fettsäuren und diese enthaltende pharmazeutischen zusammensetzungen
MY110765A (en) Compositions containing cholesteryl esters of unsaturated fatty acids
ATE192647T1 (de) Medikamente auf der basis von docosahexaensäure, als plättchenaggregationshemmer und gegen cerebralen mangel an fettsäuren, und verfahren zur herstellung.
PT920323E (pt) Nova utilizacao de fosfolipidos de origem animal em terapeutica e/ou dietetica
AU1821888A (en) Treatment or prevention of memory loss using essential fatty acid compositions
DE69832520D1 (de) Verwendung von konjugierten linoleinsäure zur behandlung von type ii diabetes
ATE284217T1 (de) Verwendung von sulphoquinovosyldiacylglycerols zur behandlung von entzündlichen hauterkrankungen
DE69633009D1 (de) Nicotinsäureester und diese enthaltende pharmazeutischen zusammensetzungen
ES2124395T3 (es) Utilizacion de esteres de diglicerina contra las impurezas de la piel.
KR0140401B1 (en) Anti-bloom triglyceride compositions
DE69205839D1 (de) Dermatologische und kosmetische Zusammensetzung.
ATE175344T1 (de) Gelbildende präparate, die optisch angereicherte gelbildner enthalten
EA200100662A1 (ru) Способ и композиция для поддержания и восстановления целостности кишки
ES2139881T3 (es) Formulacion acuosa de liberacion retardada.